| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Accounting Officer
1 company
Grant-Huerta Yanina serves as a Chief Accounting Officer at ATRA. Across recent SEC filings that breaks down to 0 buys and 7 sells. Those positions are worth an estimated $440K at current prices.
Historically, Grant-Huerta Yanina's trades have earned a below-average insider score of 26/100 across 3 rated trades. Over a 12-month horizon, 0.0% of those trades were profitable, with an average 12-month return of -40.1%.
The biggest single holding is ATRA (~$440K) as Chief Accounting Officer. The recent filings there lean toward selling, a net 5,831 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Nov 17, 2025 | ATRA Atara Biotherapeutics, Inc. | Chief Accounting Officer | Sell | 1,804 | $13.19 | $23,788.08 | -1.8% | -65.7% | - | |
| Aug 18, 2025 | ATRA Atara Biotherapeutics, Inc. | Chief Accounting Officer | Sell | 1,809 | $11.61 | $21,009.37 | -1.6% | +14.1% | - | |
| May 16, 2025 | ATRA Atara Biotherapeutics, Inc. | Chief Accounting Officer | Sell | 2,218 | $6.76 | $15,000.33 | -5.6% | +71.3% | +40.1% |